Malignant lymphoma of follicular center cell origin in humans. IV. Small transformed (noncleaved) cell lymphoma of the non‐burkitt's type

Small transformed cell lymphoma (STC) is the least common follicular center cell neoplasm in the Lukes‐Collins classification system. If the cells are homogenous in size and shape, Burkitt's lymphoma (STC‐BL) is diagnosed; otherwise STC lymphoma of the non‐Burkitt's type (STC‐nBL) is prese...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1983-10, Vol.52 (7), p.1196-1201
Main Authors: Oviatt, David L., Cousar, John B., Flexner, John M., Kurtin, Paul J., Collins, Robert D., Stein, Richard S.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Biological and medical sciences
Bone Marrow - pathology
Child
Child, Preschool
Female
Hematocrit
Hematologic and hematopoietic diseases
Humans
L-Lactate Dehydrogenase - blood
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
Lymphoma - diagnosis
Lymphoma - pathology
Lymphoma - physiopathology
Lymphoma - therapy
Male
Medical sciences
Middle Aged
Neoplasm Staging
Staining and Labeling
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Small transformed cell lymphoma (STC) is the least common follicular center cell neoplasm in the Lukes‐Collins classification system. If the cells are homogenous in size and shape, Burkitt's lymphoma (STC‐BL) is diagnosed; otherwise STC lymphoma of the non‐Burkitt's type (STC‐nBL) is present. The authors have reviewed their experience with 17 cases of STC‐nBL. This neoplasm affects all ages, both sexes equally, and most commonly is Stage IV based either on a visceral abdominal mass or bone marrow involvement. Surface immunoglobulin analysis revealed IgM in all cases tested. In spite of aggressive treatment protocols, there were only 5 of 17 (29%) clinical complete responses. Four of these five have continuous remission from 8 to 23 months after diagnosis; all four of these patients were treated with regimens containing high‐dose cyclophosphamide. Future analyses including viral studies, chromosomal analyses, and uniform treatment protocols will help determine whether STC‐nBL and Burkitt's lymphoma are truly distinct entities.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(19831001)52:7<1196::AID-CNCR2820520712>3.0.CO;2-6